Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer
Authors
Keywords
-
Journal
Breast Cancer
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-09
DOI
10.1007/s12282-023-01509-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Racial differences in predictive value of the 21-gene recurrence score assay: a population-based study using the SEER database
- (2022) Jiwoong Jung et al. Breast Cancer
- Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer–Specific Mortality Among US Women
- (2021) Kent F. Hoskins et al. JAMA Oncology
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2− Early Breast Cancer
- (2021) Mi Jeong Kwon et al. Frontiers in Oncology
- Multicenter retrospective study on the use of Curebest™ 95GC Breast for estrogen receptor-positive and node-negative early breast cancer
- (2021) Fumine Tsukamoto et al. BMC CANCER
- Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study
- (2020) Emily Heer et al. Lancet Global Health
- Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial
- (2020) Kathy S Albain et al. JNCI-Journal of the National Cancer Institute
- Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only
- (2019) Martin Filipits et al. CLINICAL CANCER RESEARCH
- Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians versus the US Population
- (2019) Ching-Hung Lin et al. JNCI-Journal of the National Cancer Institute
- Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
- (2019) Mi Jeong Kwon et al. Frontiers in Oncology
- Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer
- (2018) Ivana Sestak et al. JAMA Oncology
- BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer
- (2018) Mi Jeong Kwon et al. PLoS One
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2− early breast cancer
- (2017) Gyungyub Gong et al. Scientific Reports
- Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor–Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14
- (2016) Norman Wolmark et al. JOURNAL OF CLINICAL ONCOLOGY
- Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients
- (2015) Hideo Shimizu et al. Breast Care
- Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score
- (2015) Ivana Sestak et al. JOURNAL OF CLINICAL ONCOLOGY
- The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer
- (2014) Martin Filipits et al. CLINICAL CANCER RESEARCH
- The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
- (2013) P Dubsky et al. BRITISH JOURNAL OF CANCER
- Prospective Study of the Effect of the 21-Gene Assay on Adjuvant Clinical Decision-Making in Japanese Women With Estrogen Receptor-Positive, Node-Negative, and Node-Positive Breast Cancer
- (2013) Hideko Yamauchi et al. Clinical Breast Cancer
- Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
- (2013) Dennis C Sgroi et al. LANCET ONCOLOGY
- Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways
- (2011) Pilar Eroles et al. CANCER TREATMENT REVIEWS
- Breast Cancer Adjuvant Therapy: Time to Consider Its Time-Dependent Effects
- (2011) Ismail Jatoi et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients
- (2010) Yasuto Naoi et al. BREAST CANCER RESEARCH AND TREATMENT
- Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population
- (2010) Masakazu Toi et al. CANCER
- Clinical Utility of the 70-gene MammaPrint Profile in a Japanese Population
- (2010) M. Ishitobi et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started